Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I

被引:65
作者
Ziebell, Morten [1 ,2 ]
Holm-Hansen, Signe [1 ,2 ]
Thomsen, Gerda [1 ,2 ]
Wagner, Aase [2 ]
Jensen, Peter [1 ,2 ]
Pinborg, Lars H. [1 ,2 ,3 ]
Knudsen, Gitte Moos [1 ,2 ]
机构
[1] Rigshosp, Neurobiol Res Unit, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Rigshosp, Dept Neurol, Epilepsy Clin, DK-2100 Copenhagen, Denmark
关键词
I-123-FP-CIT (DaTSCAN); I-123-PE2I; SPECT; IN-VIVO; HIGH-AFFINITY; DOUBLE-BLIND; HUMAN BRAIN; BINDING; QUANTIFICATION; HUMANS; REPRODUCIBILITY; QUANTITATION; POSTMORTEM;
D O I
10.2967/jnumed.110.078337
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Current SPECT radioligands available for in vivo imaging of the dopamine transporter (DAT) also show affinity for monoamine transporters other than DAT, especially the serotonin transporter (SERT). The effect of this lack of selectivity for in vivo imaging is unknown. In this study, we compared the SPECT radioligands I-123-2-beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane (I-123-FP-CIT) and I-123-N-(3-iodoprop-2E-enyl)-2-beta-carbomethoxy-3 beta-(4-methylphenyl) (I-123-PE2I). I-123-FP-CIT has a 10-fold higher selectivity than I-123-FP-CIT for DAT versus SERT. Methods: Sixteen healthy individuals were scanned in random order with both radioligands. The radioligands were administered according to standard recommendations: I-123-FP-CIT was given as a bolus injection, and the ratio between the striatum and reference tissue was measured after 3 h. I-123-PE2I was administered in a bolus-infusion setup, and the nondisplaceable binding potential (BPND) was measured after 2 h. To assess the contribution of SERT to the overall SPECT signal, SERT was blocked by intravenous citalopram in 6 of the individuals. Results: The striatum-to-reference ratio - 1 of I-123-FP-CIT was on average 18% higher than the striatal BPND of I-123-PE2I. Equal doses of radioactivity resulted in 3 times higher counting rates for I-123-FP-CIT than for I-123-PE2I, both in target and in reference brain regions. Citalopram infusion led to significant reductions in both striatal (22.8% +/- 20.4%, P < 0.05) and thalamic (63.0% +/- 47.9%, P < 0.05) I-123-FP-CIT binding ratios, whereas BPND of I-123-PE2I was unaltered. Likewise, blocking of SERT led to increased (21% +/- 30.1%, P < 0.001) plasma I-123-FP-CIT, probably as a result of significant blocking of peripheral SERT binding sites. By contrast, plasma I-123-PE2I remained stable. Conclusion: I-123-FP-CIT and I-123-PE2I had approximately the same target-to-background ratios, but per injected megabecquerel, I-123-FP-CIT gave rise to 3-fold higher cerebral counting rates. We found that I-123-FP-CIT, but not I-123-PE2I, brain images have a highly interindividual but significant signal contribution from SERT. Whether the SERT signal contribution is of clinical importance needs to be established in future patient studies.
引用
收藏
页码:1885 / 1891
页数:7
相关论文
共 28 条
  • [1] Abi-Dargham A, 1996, J NUCL MED, V37, P1129
  • [2] Booij J, 1998, J NUCL MED, V39, P1879
  • [3] Booij J, 1998, EUR J NUCL MED, V25, P24
  • [4] Dopamine transporter imaging with [123I]FP-CIT SPECT:: potential effects of drugs
    Booij, Jan
    Kemp, Paul
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (02) : 424 - 438
  • [5] Booij J, 2007, J NUCL MED, V48, P359
  • [6] COMPARISON OF BOLUS AND INFUSION METHODS FOR RECEPTOR QUANTITATION - APPLICATION TO [F-18] CYCLOFOXY AND POSITRON EMISSION TOMOGRAPHY
    CARSON, RE
    CHANNING, MA
    BLASBERG, RG
    DUNN, BB
    COHEN, RM
    RICE, KC
    HERSCOVITCH, P
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (01) : 24 - 42
  • [7] Validation of [121I]β-CIT SPECT to assess serotonin transporters in vivo in humans:: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram
    de Win, MML
    Habraken, JBA
    Reneman, L
    van den Brink, W
    den Heeten, GJ
    Booij, J
    [J]. NEUROPSYCHOPHARMACOLOGY, 2005, 30 (05) : 996 - 1005
  • [8] Modeling considerations for in vivo quantification of the dopamine transporter using [11C]PE2I and positron emission tomography
    DeLorenzo, Christine
    Kumar, J. S. Dileep
    Zanderigo, Francesca
    Mann, J. John
    Parsey, Ramin V.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2009, 29 (07) : 1332 - 1345
  • [9] Synthesis and ligand binding of nortropane derivatives: N-substituted 2 beta-carbomethoxy-3 beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2 beta-carbomethoxy-3 beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter
    Emond, P
    Garreau, L
    Chalon, S
    Boazi, M
    Caillet, M
    Bricard, J
    Frangin, Y
    Mauclaire, L
    Besnard, JC
    Guilloteau, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (09) : 1366 - 1372
  • [10] MAPPING COCAINE BINDING-SITES IN HUMAN AND BABOON BRAIN INVIVO
    FOWLER, JS
    VOLKOW, ND
    WOLF, AP
    DEWEY, SL
    SCHLYER, DJ
    MACGREGOR, RR
    HITZEMANN, R
    LOGAN, J
    BENDRIEM, B
    GATLEY, SJ
    CHRISTMAN, D
    [J]. SYNAPSE, 1989, 4 (04) : 371 - 377